Wall Street Zen Upgrades Biostem Technologies (NASDAQ:BSEM) to “Sell”

Biostem Technologies (NASDAQ:BSEM) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings assumed coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Biostem Technologies Price Performance

Shares of NASDAQ BSEM opened at $3.71 on Friday. Biostem Technologies has a 1 year low of $2.25 and a 1 year high of $8.40. The firm has a 50-day moving average of $3.57 and a 200 day moving average of $4.47. The stock has a market cap of $66.22 million, a P/E ratio of -2.31 and a beta of 0.12.

Biostem Technologies Company Profile

BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.